Seer, Inc. (SEER) is an innovative life sciences company headquartered in Redwood City, California. The primary mission of the company is to break the barriers in biology and help health care providers in predicting disease in the early stages to deliver relevant treatment for patients. Through the application of technology and science, SEER strives to transform healthcare by enabling earlier, more accurate diagnosis of diseases, including cancer and neurological disorders.
Founded in 2017 by Omid Farokhzad, a leading nanomedicine scientist, Seer, Inc.t has developed Proteograph, a technique to reliably and accurately profile proteomes (the entire set of proteins expressed by an genome, cell, tissue or organism) in a high-throughput manner. These profiles can be used to identify proteins related to specific diseases or conditions, making it possible to make more accurate diagnoses and develop more efficient therapies. Seer is primarily focused on the development of diagnostic tools; however, its Proteograph can also provide valuable information for drug discovery and development.
Seer, Inc. collaborates with a number of leading research institutions and pharmaceutical companies on its development projects. These collaborations, along with their well-flourished interdisciplinary team, consisting of scientists, engineers, and healthcare professionals, have helped Seer to deliver groundbreaking results in the field of proteomics.
Seer’s research underpins the increasing importance placed on preventative and precision medicine, with an aim to transform disease management strategies and therapeutic interventions. The company has also demonstrated a strong commitment to data privacy and maintains that all patient information used in its research is de-identified to protect individual privacy.
On December 4, 2020, Seer, Inc. went public on the NASDAQ exchange under the ticker symbol "SEER." Since its public market debut, the company has gained significant attention from investors thanks to its innovative techniques and strong potential to revolutionize the field of medical diagnostics and treatment.
Ultimately, the work conducted by Seer, Inc. carries immense potential for unlocking uncharted areas of biology and driving advancements in early detection disease, particularly cancers and neurological disorders. With its innovative technology and committed team, Seer has affirmed its position at the forefront of the proteomics space, holding great promise for the future of healthcare.